Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31471662 | 0.76 | GAA (0.33) | GAAMAPT | |
| SCHEMBL5612975 | 0.70 | GAA (0.41) | GAAMAPT | |
| SCHEMBL5604886 | 0.68 | GAA (0.34) | GAAMAPT | |
| SCHEMBL309794 | 0.64 | MAPT (0.50) | GAAMAPT | |
| SCHEMBL452418 | 0.62 | GAA (0.48) | GAAMAPT | |
| SCHEMBL10912203 | 0.62 | GAA (0.37) | GAAMAPT | |
| SCHEMBL7276238 | 0.62 | GAA (0.37) | GAAMAPT | |
| SCHEMBL29469208 | 0.62 | GAA (0.37) | GAAMAPT | |
| SCHEMBL3089880 | 0.62 | GAA (0.37) | GAAMAPT | |
| SCHEMBL8102711 | 0.61 | MAPT (0.41) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037635-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | claimed |
| US-6476028-B1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2002-11-05 | — | — | US | claimed |
| EP-1037635-A1 | COMPOUNDS AND METHODS | Smithkline Beecham (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999017773-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-15 | — | — | WO | claimed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| EP-1037635-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6476028-B1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2002-11-05 | — | — | US | disclosed |
| EP-1037635-A1 | COMPOUNDS AND METHODS | Smithkline Beecham (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999017773-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | GAA 4252/4885MAPT 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.